Yucheng Wu

Yucheng Wu

Auto-generated profile, based on publicly available information

Yucheng Wu

Department of Cardiology, Taizhou People’s Hospital, Taizhou, Jiangsu, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2021 in Journal of International Medical Research
Verified
Journal Article
Open access
PDF file
YWYucheng Wu
Yucheng Wu
YLYu Lu
Yu Lu
SYShufang Yang
Shufang Yang
QZQingqing Zhang
Qingqing Zhang
Aim: To assess the effects of incretin-based therapies on β-cell function in patients with type 1 diabetes mellitus (T1DM). Methods: We searched the PubMed, Cochrane Library, Embase, and Web of Knowledge databases for eligible randomized clinical trials published up to July 2021. The inclusion criteria were patients with T1DM or latent autoimmune diabetes in adults, patients treated with dipeptidyl peptidase-4 inhibitors or glucagon like peptide-1 receptor agonists, and outcomes included one of the following: fasting plasma glucose, fasting C-peptide, postprandial C-peptide, C-peptide area under the curve (AUC), homeostasis model assessment for β cell function, and insulin resistance. The effects were analyzed using a random effect model with STATA 11.0. Results: Eight trials including 427 participants were included in the final analysis. A pooled analysis found no significant difference in fasting plasma glucose, fasting C-peptide, postprandial C-peptide, or C-peptide AUC between patients treated with incretin-based therapies and placebo. The two trials that reported changes in 2-hour postprandial C-peptide and two of the four trials that reported changes in C-peptide AUC reported increases after incretin-based therapies. Conclusion: This meta-analysis showed that incretin-based therapies did not preserve β-cell function in patients with T1DM.

9 October 2026 in Metabolic Syndrome and Related Disorders
Verified
Journal Article
Closed access
FGFei Ge
Fei Ge
QZQingqing Zhang
Qingqing Zhang
HJHao Jiang
Hao Jiang
SYShufang Yang
Shufang Yang
QCQiuping Chen
Qiuping Chen
YWYucheng Wu
Yucheng Wu
Background: The triglyceride-glucose (TyG) index has been associated with atherosclerotic cardiovascular disease (ASCVD) risk. However, the associations of TyG-related indices combined with obesity measures, including body mass index, waist circumference (WC), waist-to-height ratio, and body roundness index, with 10-year ASCVD risk across different populations remain unclear. Methods: Data from the China Health and Retirement Longitudinal Study (CHARLS; n = 8224) and the National Health and Nutrition Examination Survey (NHANES; n = 13,527) were analyzed. Weighted multivariable logistic regression, restricted cubic spline (RCS) analyses, and subgroup analyses were performed to evaluate the associations between TyG-related indices and 10-year ASCVD risk. Results: TyG and TyG-related indices were significantly associated with higher 10-year ASCVD risk in both cohorts. Nonlinear associations were observed between several TyG-related indices and ASCVD risk. Compared with the U.S. population, obesity-related TyG composite indices showed relatively stronger associations with ASCVD risk among Chinese adults. Subgroup analyses demonstrated more pronounced associations among females in the CHARLS cohort, whereas in NHANES, significant sex differences were observed only for the TyG index. Among the evaluated indices, TyG–WC showed relatively stronger associations with ASCVD risk across both datasets. Conclusion: TyG-related indices were significantly associated with 10-year ASCVD risk across Chinese and U.S. populations, although the strength of these associations varied between populations. TyG–WC may provide additional value for ASCVD risk assessment. Further longitudinal studies are warranted to validate these findings and clarify the underlying mechanisms.

31 January 2024
Verified
Preprint
Open access
YWYucheng Wu
Yucheng Wu
JLJie Lin
Jie Lin
BGBenbingdi Gong
Benbingdi Gong
LWLichun Wang
Lichun Wang
QWQiuchen Wang
Qiuchen Wang
KXKai Xu
Kai Xu
Aims: Left atrial appendage (LAA) occlusion for Atrial fibrillation (AF) is an invasive therapy to reduce stroke incidence and death. Cardiac rehabilitation based on exercise training has become part of the standard care for patients with heart disease. Studies are needed to evaluate the effects of cardiac rehabilitation on exercise capacity, cardiac function, quality of life (QoL), residual permeability, device endothelialization and safety in AF patients with LAA occlusion. Methods: A single-center, three-month randomized controlled trial comparing an exercise-based cardiac rehabilitation program with a control group was conducted. AF patients underwent LAA occlusions were randomized to exercise-based cardiac rehabilitation (rehabilitation group) versus usual care (control group). All patients received assessments of echocardiography, cardiac CT, scale survey, physical function and exercise capacity. All analyses were performed using SPSS 19.0. Results: Finally, 33 patients in control group and 30 patients in rehabilitation group entered final analysis. The six-minute walk distance, handgrip strength, leg strength and left ventricular systolic function increased significantly after the study period in the rehabilitation group compared with baseline, which have significant interactions with control group. Significant differences between groups were found for the mental and physical component summary scales on SF-36, also in all of the 8 subscales. The incidence of peri-device leak and incomplete endothelialization in cardiac rehabilitation group were both significantly lower than that in control group. There was no significant difference in the incidence of adverse events between the two groups. Conclusion: Cardiac rehabilitation could promote device endothelialization and reduce peri-device leak in AF patients with LAA occlusion, which also has benefits in QoL, exercise capacity, physical function and systolic left ventricular function.